“Shawn was responsible for high-level planning and oversight of a formulation and aseptic fill project that I managed from the client side. Shawn and his group did a fantastic job on the project, delivering excellent results on a very tight timeline. It was a pleasure to deal with Shawn, and I highly recommend him.”
About
Activity
-
Drug development is a very lengthy, expensive process, and reports indicate that every day a drug launch is delayed, millions of dollars in revenue…
Drug development is a very lengthy, expensive process, and reports indicate that every day a drug launch is delayed, millions of dollars in revenue…
Liked by Shawn Cain
-
With nearly two-thirds of the early-development pipeline coming from small and emerging biopharma, there is a great need to accelerate programs into…
With nearly two-thirds of the early-development pipeline coming from small and emerging biopharma, there is a great need to accelerate programs into…
Liked by Shawn Cain
-
We are hiring for an instructional position: The Department of Biomedical Engineering at the University of Michigan is hiring a Lecturer in BME…
We are hiring for an instructional position: The Department of Biomedical Engineering at the University of Michigan is hiring a Lecturer in BME…
Liked by Shawn Cain
Experience & Education
Publications
-
Biotechnology Devices: Where Man Meets Machine
BIO International Convention, May 9, 2007, Boston, MA
Panelist at BIO
-
Developing Innovative Liver Assist Devices
In3 Medical Device Summit, June 22, 2006, San Francisco, CA
Presentation/Poster
-
Chapter 5: Preparing to Be the Focus of a Due Diligence Exercise
The Expert’s Guide to Healthcare Product Due Diligence, (The Food and Drug Law Institute), Editors C. Osborne, B. Silverstein
Book Chapter on being the target of a Due Diligence event
-
Challenges in the Development of a Cell Based Combination Product
BioWest 2005 Conference, November 9, 2005, Denver, CO
Presentation
-
Manufacturing and Quality Compliance for a Cell Based Medical Device
Regulatory Affairs Professionals Society 2005 Annual Conference and Meeting, October 18, 2005, Baltimore, MD
Presentation
-
Development of the HepatAssist® Bioartificial Liver
Regulatory Affairs Professionals Society 2005 Annual Conference and Meeting, October 17, 2005, Baltimore, MD
Presentation
-
Comparison of Major Phase I and phase II Metabolism Reactions in Cryopreserved Cyno Monkey and Human Hepatocytes
Snodgrass, B, Gagne, P, Picano, P, Lohnes K, Cain, S, Zhang, G, Patten, C and Crespi, C, (2005), 44th Society of Toxicology (SOT), New Orleans, LA
Presentation/Poster
-
Development of Combination Devices
Drug Information Association 39th Annual Meeting, June 14th, 2003, San Antonio, TX
Presentation
-
Due Diligence and Its Impact on Post Acquisition Integration
Regulatory Affairs Professionals Society 2002 Annual Conference and Meeting, October 9, 2002, Washington, D.C
Presentation
-
Functional In Vitro Assessment of Varying Cell Mass of Cryopreserved Hepatocytes in the Clinical HepatAssist Liver Assist System
The 39th Meeting of the Society for Cryobiology, Breckenridge, CO, July 28 – 31, 2002
Presentation/Poster
-
In Vitro Assessment of Cryopreserved Porcine Hepatocytes as Used in the Clinical HepatAssist Liver Assist System
American Society for Artificial Internal Organs 48th Annual Conference, New York, June 13 – 15, 2002
Poster Presentation
-
Elution of Cryopreserved Hepatocytes Using a Hollow Fiber Membrane Bioreactor
CRYO 2000, 37th Annual Meeting of the Society for Cryobiology, July 30 - August 1, 2000, Boston, MA, USA, Journal of the Society for Cryobiology, Volume 41, Number 4, December 2000
Peer Reviewed Journal and Presentation
-
Comparison of Analytical Methods for Quantitation of Isolated Porcine Hepatocyte Yields
Tissue Engineering 6:3
Peer Review Journal
-
In vitro Studies Toward the Functional Optimization of a Bioartificial Liver Without Microcarriers
Meeting of the Tissue Engineering Society, November 30 - December 3, 2000, Tissue Engineering, Vol. 6, No. 6, 2000
Peer Reviewed Journal and Presentation
-
A “Closed” System Method for the Processing and Cryopreservation of Porcine Hepatocytes for Use in a Bioartificial Liver
The 35th Annual Meeting of the Society for Cryobiology, Pittsburgh, Pennsylvania, July 11 – 16, 1998
Poster Presentation
-
Large Scale Cryopreservation of Porcine Hepatocytes for Commercial Application
The 35th Annual Meeting of the Society for Cryobiology, Pittsburgh, Pennsylvania, July 11 – 16, 1998
Poster Presentation
-
The Effects of Cell Density on the Cryopreservation of Porcine Hepatocytes
The 35th Annual Meeting of the Society for Cryobiology, Pittsburgh, Pennsylvania, July 11 – 16, 1998
Poster Presentation
-
In Vitro Performance of the HepatAssistTM 2000 Extracorporeal Liver Assist System Using Primary Porcine Hepatocytes
BioSym'96 International Symposium on Hollow Fiber Bioreactor Technology, Boston, MA, November, 1996
Poster Presentation
-
Large Scale Cryopreservation of Porcine Hepatocytes for the Clinical Treatment of Acute Liver Failure
Cell Transplantation, Vol. 5, Number 5S-2
Peer Review Journal
-
In Vitro Testing of the HepatAssistTM 2000 Extracorporeal Liver Assist System and Porcine Hepatocyte Suspension
Bioartificial Organs: Science and Technology Engineering Foundation Conference, Nashville, TN, July, 1996
Poster Presentation
-
Scale Cryopreservation of Porcine Hepatocytes for the Clinical Treatment of Acute Liver Failure
The Cell Transplant Society Third International Congress, Miami Beach, Florida, September, 1996
Poster Presentation
-
Mammalian Liver Cells For Artificial Liver Support
Cell Transplantation, Vol. 5, No. 3, 1996
Peer Review Journal
-
Bullseye Progesterone Diagnostic Kit
Frontier to the Future - American Breeders Service, Orlando, Florida, January, 1991
Poster Presentation
-
High Performance Immobilization Membrane for Diagnostic Immunoassays
Clinical Chemistry, Vol. 33, No. 9
Peer Review Journal
-
High Performance Immobilization Membrane for Diagnostic Immunoassays
Nineteenth Annual Oak Ridge Conference on Advanced Analytical Concepts for the Clinical Laboratory, San Antonio, Texas, April, 1987
Poster Presentation
Patents
-
Method of Cryopreserving Hepatocytes
Issued US 6,136,525
An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99%. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual cryoprotectant media.
-
Removal of Agent From Cell Suspension
Issued US 6,068,775
The invention relates to a method of removing an agent from a suspension of cells using a semi-permeable membrane. In one aspect of the invention, the cells are used to bioprocess a biological fluid after removal of the agent.
-
High Flow Technique for Harvesting Mammalian Cells
Issued US 5,912,163
The invention is based in part on the observation that significant portions of porcine livers appear to remain intact after perfusion by standard methods, suggesting that the perfusion procedures employed do not result in complete enzymatic digestion. Recovery of cells is therefore substantially lower than would be possible if the organs were thoroughly digested. It is found that increased perfusion flow rate, occlusion of at least one major blood vessel leading out of the organ, increased…
The invention is based in part on the observation that significant portions of porcine livers appear to remain intact after perfusion by standard methods, suggesting that the perfusion procedures employed do not result in complete enzymatic digestion. Recovery of cells is therefore substantially lower than would be possible if the organs were thoroughly digested. It is found that increased perfusion flow rate, occlusion of at least one major blood vessel leading out of the organ, increased enzymatic digestion time, and vigorous tissue dissociation techniques can be combined to afford a uniquely high yield of viable cells.
-
Method of Thawing Cryopreserved Cells
Issued US 5,895,745
The invention features a method of processing cryopreserved cells by thawing and equilibrating the cells at warm temperatures (e.g., between 30.degree. C. and 43.degree. C). Either the cell suspension in the cryoprotective medium is thawed to a temperature between 35.degree. C. and 43.degree. C. or the cryoprotective medium is equilibrated with a culture medium at a temperature between 35.degree. C. and 43.degree. C., or both steps are carried out at the warm temperatures. By thawing and…
The invention features a method of processing cryopreserved cells by thawing and equilibrating the cells at warm temperatures (e.g., between 30.degree. C. and 43.degree. C). Either the cell suspension in the cryoprotective medium is thawed to a temperature between 35.degree. C. and 43.degree. C. or the cryoprotective medium is equilibrated with a culture medium at a temperature between 35.degree. C. and 43.degree. C., or both steps are carried out at the warm temperatures. By thawing and equilibrating the cryopreserved cells at warm temperatures, the viability, (especially after 3 hours of culture), and metabolic activity (i.e., diazepam metabolism) of the cells can be improved over traditional cold cell processing (i.e., at temperatures of between 2.degree. C. and 8.degree. C.).
-
A Closed System For Processing Cells
Issued US 5,858,642
The invention features a method of processing cells in a closed system that results in a suspension of cells in a transfer vessel containing a target number of cells. The number of cells in the closed vessel is determined from the cell concentration (i.e., the number of viable cells/mL) in the closed vessel and the total volume of the suspension in the closed vessel. The volume of the suspension in the closed vessel can be determined from the weight of the suspension and its density. In…
The invention features a method of processing cells in a closed system that results in a suspension of cells in a transfer vessel containing a target number of cells. The number of cells in the closed vessel is determined from the cell concentration (i.e., the number of viable cells/mL) in the closed vessel and the total volume of the suspension in the closed vessel. The volume of the suspension in the closed vessel can be determined from the weight of the suspension and its density. In particular, the cells are preserved in a protective medium and are recovered substantially free of the protective medium in a closed vessel containing the known number of cells in a suspension.
-
Cryopreserved Hepatocytes and High Viability and Metabolic Activity",
Issued US 5,795,711
An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99% and a metabolic activity 50-80% of fresh hepatocytes. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual…
An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99% and a metabolic activity 50-80% of fresh hepatocytes. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual cryoprotectant media.
Recommendations received
3 people have recommended Shawn
Join now to viewMore activity by Shawn
-
Join me with the PCI team at the Tokyo Big Sight Tokyo for INTERPHEX Week on June 26 - 28, 2024. Drop me a message to arrange a meeting at Booth…
Join me with the PCI team at the Tokyo Big Sight Tokyo for INTERPHEX Week on June 26 - 28, 2024. Drop me a message to arrange a meeting at Booth…
Liked by Shawn Cain
-
The journey from early-phase clinical trials to successful commercial launch for an injectable drug product is complex and multifaceted. Choosing…
The journey from early-phase clinical trials to successful commercial launch for an injectable drug product is complex and multifaceted. Choosing…
Liked by Shawn Cain
-
BIO International Convention 2024 is in full swing. Meet the PCI Pharma Services team this week at Booth#6050 to learn more about the scalability of…
BIO International Convention 2024 is in full swing. Meet the PCI Pharma Services team this week at Booth#6050 to learn more about the scalability of…
Liked by Shawn Cain
-
What a fantastic seminar coming in Basel on June 18th. I look forward to seeing you there!
What a fantastic seminar coming in Basel on June 18th. I look forward to seeing you there!
Liked by Shawn Cain
-
Jeff Clement recently spoke with Susan Haigney from Pharmaceutical Technology before the 2024 Bio International Convention on incorporating robotics…
Jeff Clement recently spoke with Susan Haigney from Pharmaceutical Technology before the 2024 Bio International Convention on incorporating robotics…
Liked by Shawn Cain
-
Please join me at the PCI Seminar in Basel for an insightful conversation discussing the key considerations and critical success factors in…
Please join me at the PCI Seminar in Basel for an insightful conversation discussing the key considerations and critical success factors in…
Liked by Shawn Cain
-
Working with our partners to make a difference in the lives of patients. We are fortunate!
Working with our partners to make a difference in the lives of patients. We are fortunate!
Shared by Shawn Cain
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Shawn Cain in United States
-
Shawn C.
-
Shawn Cain
Consumer at Citadel Global Equities
-
Shawn Cain
Chief Information Officer at Tryon Direct
-
Shawn Cain
VP Operation Desert States at CASCADE DRILLING
48 others named Shawn Cain in United States are on LinkedIn
See others named Shawn Cain